Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials
暂无分享,去创建一个
S. Klarenbach | R. Tsuyuki | P. Tandon | V. Bain | Ross T. Tsuyuki | Puneeta Tandon | Vincent G. Bain
[1] S. Sarin,et al. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response noradrenaline versus terlipressin in the treatment of HRS-1 , 2008 .
[2] A. Sanyal,et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.
[3] F. Fabrizi,et al. Meta‐analysis: terlipressin therapy for the hepatorenal syndrome , 2006, Alimentary pharmacology & therapeutics.
[4] N. Stockbridge,et al. Blood pressure as an example of a biomarker that functions as a surrogate , 2006, The AAPS Journal.
[5] J. Vinel,et al. Treatment of Hepatorenal Syndrome as Defined by the International Ascites Club by Albumin and Furosemide Infusion According to the Central Venous Pressure: A Prospective Pilot Study , 2005, The American Journal of Gastroenterology.
[6] Y. Lacasse,et al. From the authors , 2005, European Respiratory Journal.
[7] R. MacLaren,et al. Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] F. Wong,et al. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.
[9] C. Broelsch,et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. , 2004, European journal of medical research.
[10] K. Demır,et al. Terlipressin and albumin combination treatment in hepatorenal syndrome. , 2003, Hepato-gastroenterology.
[11] M. Lafortune,et al. Octreotide in hepatorenal syndrome: A randomized, double‐blind, placebo‐controlled, crossover study , 2003, Hepatology.
[12] A. M. Solyman,et al. Role of therlipressine and octreotide in type I hepatorenal syndrome (HRS) , 2003 .
[13] D. Chelãrescu,et al. Propranolol administration on post surgical infections in cirrhotic patients , 2003 .
[14] E. Esrailian,et al. Octreotide/midodrine therapy significantly improves survival in type 1 hepatorenal syndrome: Analysis of 53 treated patients & 21 controls , 2003 .
[15] A. M. Solyman,et al. Essential systemic hypertension and viral chronic liver disease , 2003 .
[16] T. Sauerbruch,et al. Vasoactive treatment of hepatorenal syndrome type 1 (HRS1) with midodrine, octreotide and albumin , 2003 .
[17] D. Chelãrescu,et al. Captopril in low dose associated with octreotide in hepatorenal syndrome: A randomized study , 2003 .
[18] R. Gupta,et al. Beneficial effects of terlipressin in hepatorenal syndrome: A prospective, randomized placebo‐controlled clinical trial , 2003, Journal of gastroenterology and hepatology.
[19] D. Fish,et al. Assessing renal function in cirrhotic patients: problems and pitfalls. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] F. Roudot-thoraval,et al. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study , 2002, Hepatology.
[21] I. Colle,et al. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: A retrospective analysis , 2002, Journal of gastroenterology and hepatology.
[22] G. Constantinescu,et al. Reversal of type I hepatorenal syndrome (HRS) with therlipressine and octreotide , 2002 .
[23] R. Moreau,et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. , 2002, Gastroenterology.
[24] W. Jiménez,et al. Effects of terlipressin administration with and without albumin in hepatorenal syndrome (HRS). A phase II study , 2002 .
[25] Ľ. Beňa,et al. Hepatorenal syndrome type 1 in patients with acute alcoholic hepatitis treated with continual terlipressin infusion in combination with albumin plasmaexpansion , 2002 .
[26] P. Fiévet,et al. Effect of terlipressin (Glypressin®) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study* , 2002, European journal of gastroenterology & hepatology.
[27] J. Mauillon,et al. Hepatorenal syndrome in cirrhotic patients: terlipressine is a safe and efficient treatment; propranolol and digitalic treatments: precipitating and preventing factors? , 2000, American Journal of Gastroenterology.
[28] R. Bataller,et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. , 2000, Journal of hepatology.
[29] A. Gerbes,et al. Long‐term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine , 1999, Hepatology.
[30] M. Prados,et al. Response and progression in recurrent malignant glioma. , 1999, Neuro-oncology.
[31] G. Guyatt,et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. , 1999, JAMA.
[32] Y. Baruch,et al. Low‐dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end‐stage heart failure , 1999, Journal of internal medicine.
[33] R. Orlando,et al. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. , 1999, Clinical nephrology.
[34] P. Angeli,et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide , 1999, Hepatology.
[35] A. Burroughs,et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine , 1999, The Lancet.
[36] L. Legault,et al. Glomerular filtration rate measurement in cirrhotic patients with renal failure. , 1998, Clinical nephrology.
[37] O. Bulbena,et al. Effect of Subcutaneous Administration of Octreotide on Endogenous Vasoactive Systems and Renal Function in Cirrhotic Patients with Ascites , 1998, Digestive Diseases and Sciences.
[38] E. Casiglia,et al. Acute effects of the oral administration of midodrine, an α‐adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites , 1998, Hepatology.
[39] R. Moreau,et al. Beneficial effects of the 2‐day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome , 1998, Journal of hepatology.
[40] W. Jiménez,et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion , 1998, Hepatology.
[41] S. Nasraway,et al. Pretransplant renal dysfunction predicts poorer outcome in liver transplantation. , 1997, Clinical nephrology.
[42] R. Moreau,et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. , 1997, Journal of hepatology.
[43] Richard Sylvester,et al. Analysis and presentation , 1997 .
[44] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[45] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[46] J. Schölmerich,et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.
[47] G. Klintmalm,et al. IMPACT OF PRETRANSPLANT RENAL FUNCTION ON SURVIVAL AFTER LIVER TRANSPLANTATION , 1995, Transplantation.
[48] P. Angeli,et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. , 1994, Archives of internal medicine.
[49] G. Jennings,et al. Impaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis. , 1993, Gastroenterology.
[50] W. Jiménez,et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. , 1993, Gastroenterology.
[51] R Simon,et al. Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. , 1992, Journal of the National Cancer Institute.
[52] H L Greene,et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. , 1991, The New England journal of medicine.
[53] S. Ellenberg. Surrogate end points in clinical trials. , 1991, BMJ.
[54] J. Ruskin,et al. The cardiac arrhythmia suppression trial (CAST). , 1989, The New England journal of medicine.
[55] D. V. van Thiel,et al. Effects of renal impairment on liver transplantation. , 1987, Gastroenterology.
[56] A. Arieff,et al. Unpredictability of clinical evaluation of renal function in cirrhosis. Prospective study. , 1987, The American journal of medicine.
[57] T. Starzl,et al. Recovery from "hepatorenal syndrome" after orthotopic liver transplantation. , 1973, The New England journal of medicine.
[58] R. Moreau. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. , 2004, Journal of hepatology.
[59] M. Navasa,et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. , 2004, Journal of hepatology.
[60] M. Voiculescu,et al. 224 Association of a selective endothelin-a receptor antagonist (ET-A RA) could improve the outcome of patients with hepatorenal syndrome (HRS) , 2004 .
[61] O. Moine,et al. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study. , 2001, Acta gastro-enterologica Belgica.
[62] C. Chagneau,et al. Octreotide in the treatment of the hepatorenal syndrome in cirrhotic patients. , 1999, Journal of hepatology.
[63] A. J. Man in 't Veld. Surrogate end points in clinical trials. , 1997, Blood pressure. Supplement.